PharmaSeq

Home Company News & Events Press Releases 2013 National Cancer Institute Awards Combinatorial Chemistry Grant to PharmaSeq

Press Releases

National Cancer Institute Awards Combinatorial Chemistry Grant to PharmaSeq

National Cancer Institute Awards Combinatorial Chemistry Grant to PharmaSeq

Monmouth Junction, NJ, February 14, 2013. PharmaSeq, Inc., announced today the receipt of a Phase I SBIR grant for a project entitled "Characterization of low-abundance proteins using combinatorial peptide libraries on light-activated p-Chips". The grant was awarded by the National Cancer Institute of the NIH.

The grant's objective is to demonstrate the feasibility of creating ID-encoded combinatorial peptide libraries appropriate for identification of auto-antibodies to tumor- associated antigens (TAAs), an approach that may become a very valuable tool in the fight against cancer. Combinatorial libraries are collections of molecules that are systematically synthesized in large numbers from a limited numbers of molecular building blocks. In the current project, this involves combinations of different amino acids to construct a peptide library that contain compounds capable of binding to tumor antigen-specific auto-antibodies, and thus capable to identify the auto-antibody.

"The clinical use of TAA auto-antibodies requires a system that can simultaneously detect multiple anti-TAAs since any individual antibody would not provide sufficient sensitivity and specificity. Combinatorial libraries, with their enormous diversity, have the potential to resolve the complexity of identifying tumor markers against high background protein levels, yet have fallen out of favor due to difficulties with indexing individual particles," states Dr. Wlodek Mandecki, President and Chief Scientific Officer of PharmaSeq, Inc. Mandecki adds, "PharmaSeq's light-activated p-Chip platform resolves this problem by providing a means to identify the composition of each particle through electromagnetic querying of the particle using p-Chips. Silicon-based p-Chips are an ideal substrate for building combinatorial libraries due to their very small size (0.5 mm square), low cost and their resistance to chemical challenges used in typical syntheses."

The project is a collaboration with David A. Spiegel, M.D., Ph.D., Associate Professor in the Department of Chemistry at Yale University. Dr. Spiegel's laboratory will perform the organic synthesis to produce the peptide libraries with PharmaSeq designing the biological assays as well as the manufacturing of flow-based systems for performing the sorting and data assessment for the experiments.

"This award is an important landmark for PharmaSeq in that it recognizes the utility of the p-Chip platform for designing and testing advanced assay techniques for determining patient-specific tumors," further explains Mandecki. "The synthesis of libraries on the surfaces of p-Chips will provide researchers and clinicians with a very valuable tool in the fight against many diseases. We are particularly pleased to be working with Dr. Spiegel and his colleagues at Yale."

For further information, please contact Dr. Richard G. Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100. Find us on the web at: www.pharmaseq.com.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852


Find us on the web at: www.pharmaseq.com.


Home Company News & Events Press Releases 2013 National Cancer Institute Awards Combinatorial Chemistry Grant to PharmaSeq